← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Danaher DHR $158B	912	+15	+2%	$43.7B
2	2 Thermo Fisher Scientific TMO $249B	911	-4	-0.4%	$43.6B
3	3 Novartis NVS $279B	848	+17	+2%	$21.5B
4	4 Agilent Technologies A $49.1B	591	+7	+1%	$16.4B
5	5 Illumina ILMN $41B	458	+25	+6%	$24.2B
6	6 Regeneron Pharmaceuticals REGN $80.1B	448	-5	-1%	$21B
7	7 Revvity RVTY $17B	324	+2	+0.6%	$4.82B
8	8 Myriad Genetics MYGN $397M	284	+3	+1%	$4.01B
9	9 Charles River Laboratories CRL $14.4B	262	+4	+2%	$2.6B
10	10 Ionis Pharmaceuticals IONS $7.1B	238	+4	+2%	$3.58B
11	11 Alnylam Pharmaceuticals ALNY $30B	194	-4	-2%	$3.68B
12	12 Bruker BRKR $8.47B	190	+6	+3%	$2.75B
13	13 DELISTED SANGAMO THERAPEUTICS INC SGMO	156	+11	+8%	$747M
14	14 Azenta AZTA $1.63B	150	+14	+10%	$668M
15	15 Sarepta Therapeutics SRPT $1.78B	128	+14	+12%	$794M
16	16 Arrowhead Research ARWR $8.25B	112	+10	+10%	$559M
17	17 Precigen PGEN $2.64B	107	+7	+7%	$2.18B
18	18 DELISTED bluebird bio BLUE	104	+21	+25%	$742M
19	19 Standard BioTools LAB $248M	104	-3	-3%	$788M
20	ISEE 20 DELISTED IVERIC bio, Inc. Common Stock ISEE	98	+25	+34%	$1.18B
21	21 Pacific Biosciences PACB $619M	86	-2	-2%	$230M
22	22 PTC Therapeutics PTCT $4.98B	84	+19	+29%	$601M
23	23 Ultragenyx Pharmaceutical RARE $1.47B	81	+4	+5%	$816M
24	24 Invesco Biotechnology & Genome ETF PBE $421M	74	+1	+1%	$113M
25	NSTG 25 DELISTED NanoString Technologies, Inc. NSTG	68	+6	+10%	$188M